Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer. Cyclooxygenase-2 is overexpressed in bladder cancer cells ...

BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...

NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been screened in a randomized Phase 2 study of the Company’s novel, ...

Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. This is an ASCO Meeting Abstract from the 2017 Genitourinary Cancers ...

Cancer treatment by modulation of genetic alteration has been widely examined and adopted in clinical trials. Since the development and progression of cancer is generally caused by multiple genetic ...

Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, with around half of patients affected. Prognostic tests can help identify patients ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors. Findings from an analysis of a phase 2 trial demonstrated that ...

A medical expert has revealed the six common habits that sabotage our bladder health, leading to incontinence or even deadly cancer. It is easy to overlook our bladders until they start causing ...